Speakers from ImmunoGen, Pfizer, & CEOs from IONTAS and Aridis Pharmaceuticals to present at Protein Discovery Summit.


John Lambert, Executive Vice President at ImmunoGen, and Seema Kumar, Principal Scientist at Pfizer, will be giving presentations at the Antibody Drug Conjugates Conference, which is happening on December 5th – 6th, 2016. Meanwhile, John McCafferty, Chief Executive Officer at IONTAS, and Vu Truong, Chief Executive Officer at Aridis Pharmaceuticals will be giving presentations at […]

Continue Reading

Samir Khleif, Director, GA Cancer Center at Augusta University, to speak at GTCbio’s Inaugural Cancer Immunotherapy Conference (November 7-8, 2016 in San Francisco CA)


Dr. Khleif is the Director of the Georgia Cancer Center at Augusta University and is an internationally recognized cancer physician, scientist, administrator and educator whose diverse interests and experiences have allowed him to develop an unparalleled skill set. His medical background and research experience has focused primarily on translational research and trials, with a focus […]

Continue Reading

A glimpse from inside the M3D Summit.


Michael Naso from @JanssenUS presents “The Future of Biotherapeutics” at our #M3DSummit “We are rapidly progressing our basic understanding of molecules and pathways that drive health and disease. The logical outcome of these efforts will be the identification of therapeutic intervention strategies that are specific for those pathways that are at the heart of the disease […]

Continue Reading

Prof. Terry Hébert from McGill University will discuss “Assessing Bias and Allostery in GPCRs using Conformational Biosensors” at GTCbio’s GPCR in Drug Discovery Conference in Boston, MA


Ligand-biased signaling could have a significant impact on drug discovery programs in the pharmaceutical industry. As such, many investigators and screening campaigns are now being directed at a larger section of the signaling responses downstream of an individual G protein-coupled receptor. Biosensor-based platforms have been developed to capture signaling signatures. Despite the ability to use […]

Continue Reading

Kevin Morris, from the City of Hope, to discuss “Genomic Dark Matter; The Complexities of Non-Coding RNA from Mechanism to Therapeutics” at 7th Non-Coding RNA & RNAi Therapeutics Conference


Observations over the past decade have demonstrated that exogenously introduced non-coding RNAs can transcriptionally modulate gene expression in human cells by recruiting silent state epigenetic marks to target loci. Dr. Kevin Morris will present evidence here suggesting that long non-coding RNAs (lncRNAs), which are antisense to particular protein-coding genes, function in human cells as effector […]

Continue Reading

Erin Keaney, Novartis, will give a presentation at 11th Drug Design & Medicinal Chemistry (September 12-13, 2016 in Boston, MA)


The autophagy process is an essential pathway utilized by cells to breakdown damaged cellular constituents and provide the cell with energy. A variety of diseases including cancer and neurodegeneration have been linked to the activation or inhibition of autophagy. In an effort to identify pharmacological agents to inhibit this process, Dr. Keaney’s group utilized a […]

Continue Reading

Richard Buller, VP at Pfizer, to Give a Keynote at GTCbio’s Biomarker Summit Europe 2016


Richard E. Buller, Vice President of Oncology, Clinical Development & Head of Global Product Development at Pfizer will give a keynote presentation on, “Feedback Loops Between Biomarkers and Targeted Agents in Clinical Trials and Beyond: Lessons from Anaplastic Lymphoma Kinase (ALK+) Driven Non-Small Cell Lung Cancer (NSCLC)“ at GTCbio’s Biomarker Summit Europe 2016 to be […]

Continue Reading

Diana Colleluori from Bluebird Bio will present, “Quality Control Considerations for Commercialization of Autologous Cell Products” at 3rd Cell & Gene Therapy (Sept, 12-13, 2016 in Boston, MA)


Quality expectations are not based on the speed of the approval process, thus leading to quality control challenges in expedited product development cycles as exists for gene therapies.  Most often, there is less product information and limited data available at the time of marketing submissions.  Sponsors are faced with overcoming many quality challenges, including analytical […]

Continue Reading

CNS Diseases World Summit- September 12-15, 2016 in Boston.


We are excited to announce the CNS Diseases World Summit, to be held on September 12-15, 2016 in Boston, MA. This meeting provides an interactive learning and relationship-building forum for all players in the CNS field. Colleagues from industry, academia, government agencies, and financing bodies will gather at the interface of research, partnerships, funding, and commercialization to find […]

Continue Reading

Lee E. Walko from Omni Tech International will give a Speak at the 7th Biobased Chemicals Commercialization & Partnering Conference (July 7-8, 2016, Boston)


Lee E. Walko, Biobased Business Development Manager at Omni Tech International, will give a talk titled, “The Need for Speed,” at GTCbio’s 7th Biobased Chemicals Commercialization & Partnering Conference to be held on July 7-8, 2016 in Boston, MA.   Omni Tech and Biobased Global have teamed up to focus on applying lean startup techniques […]

Continue Reading